Kansarka naasaha & ugxan sidaha
Haddii aad tahay bukaanka kansarka naasaha iyo ugxan-sidaha, waxa dhacda in aad ogaato in aad tahay kansar ku dhacay isbeddelka BRCA1/2 ka dib markii aad ka gudubto tijaabada hidde-sidaha, noloshaadana waa la badbaadshay. Sida laga soo xigtay Shabakadda Oncologist Global, Niraparib, oo ah daroogo la beegsaday oo lagu bartilmaameedsaday hidda-wadaha PARP, ayaa loo gudbin doonaa suuqgeyn rubuci afaraad ee sanadkan sababtoo ah wejigeeda cajiibka ah ee III natiijooyinka tijaabada caafimaad. Sababtoo ah xogta tijaabada caafimaad ee cajiibka ah ee dawadan, waa la hubaa Waxaa hubaal ah in daawada ay ansixin doonto FDA. Shirkadda horumarinta daroogada ee bartilmaameedka ah ee Tesaro qiimihiisu wuxuu kor uga kacay $37 ilaa $77 isla markiiba horumarkan dartiis.
Daawo noocee ah waa Niraparib?
It is an oral targeted drug that targets the PARP gene and is not effective for any cancer. It mainly targets cancers with mutations in the BRCA1 / 2 gene, such as kansarka ugxansiduhu and breast cancer. It reflects the “precision treatment” concept of modern medicine. Patients with ovarian and kansarka naasaha need genetic testing to find out if they have a BRCA1 / 2 mutation.
Sidee la yaab leh daaweynta Niraparib?
Tesaro ayaa sii daayay xogta bukaan-socodka ee Wajiga III ee Niraparib ee bukaannada kansarka ugxan-sidaha ee soo laba kacleeyay ka dib daaweynta kiimiko ee sare. Natiijooyinku waxay muujiyeen in kansarka ugxan-sidaha ee leh isu-beddelka hidda-wadaha BRCA, Niraparib ayaa afka laga qaadan jiray hal mar maalin kasta, celceliska badbaadada cudur-la'aanta waxay ahayd 21 bilood, halka kooxda xakamaynta (Bukaannada qaata kemotherabi keligood) ay heleen badbaado bilaash ah 5.5 bilood. . 21 bilood vs 5.5 bilood, wakhtiga badbaadadu waa ku dhawaad 4 jeer ka dheer! Tiradani waa mid aad looga naxo, sababtoo ah badbaadada dheeraadka ah ee badi daawooyinka cusubi waa dhowr bilood oo keliya. Si kale haddii loo dhigo, bukaanka qaba isbeddellada BRCA ee isticmaala Niraparib waxay noolaan karaan celcelis ahaan in ka badan 21 bilood. Tani waxay aad ula yaabban tahay bukaanada qaba kansarka ugxansidaha sare ee soo noqnoqda.
Kansar noocee ah ayuu Niraparib daweyn karaa?
PARP iyo BRCA waa labada hidde ee masuulka ka ah hagaajinta isbeddellada DNA ee unugyada, waana "habka ilaalinta midig iyo bidix" si loo ilaaliyo caafimaadka unugyadeena. Sababtoo ah saameynta deegaanka, isbeddellada DNA-da waxay ku dhacaan jirkeena wakhti kasta iyo meel kasta, laakiin sababtoo ah jiritaanka labadan hab ee ilaalinta, ka dib markii isbeddellada DNA-da la damaanad qaado, in ka badan 99.9999% ayaa si guul leh loo hagaajin karaa, haddii kale dhacdooyinka kansarka. aad ayuu uga sarreeyaa hadda .
Laakin dadka qaarkiis, sababo la dhalan karo ama la helay awgood, unugga BRCA hidda-wade laftiisa waa is beddelaa oo lumiyaa shaqadiisa, sidaa darteed suurtogalnimada hagaajinta ka dib beddelka DNA-da ayaa aad u daciifa, isbeddellada hidde-sidaha ayaa si dhakhso ah u urursan doona. Suurtagalnimada kansarka ee kooxdan ayaa aad u kordheysa.
Although PARP inhibitors are mainly targeted at breast and ovarian cancer, some patients with other cancers also carry BRCA mutations or other DNA repair defects. They theoretically use PARP-targeted drugs to work well, including some kansarka qanjirka 'prostate'. , Fallopian tube cancer, pancreatic cancer, childhood ba'an cudurka myeloid leukemia, etc. Clinical trials for these cancers are ongoing, and the world is waiting to see the results.
